LAL, kinetic chromogenic, recombinant factor C: three ways to the same figure
The masking phenomenon known as low endotoxin recovery means a formulation can return a clean result while containing endotoxin the assay cannot see.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Stability
What would make a difference is not a regulator. It is three lines on a certificate, all of which are already known to whoever wrote it.
We asked twenty companies three questions in writing. Has a formal stability study been performed on this product, under what conditions and for how long. Is residual moisture determined on the finished lyophilised product, and against what specification. Is the shelf life stated on the certificate a retest date or an expiry date, and what data supports it. Six companies answered all three. Five answered one or two. Nine did not reply to two messages sent four weeks apart. As always we record a refusal as a refusal and a silence as a silence.
Two methods dominate. Karl Fischer titration determines water specifically, by a stoichiometric reaction with iodine, and is the reference method; the coulometric variant works on the small sample masses a single vial provides. Loss on drying is simpler and less specific, measuring total volatile mass lost under defined heating, which for a formulation containing residual organic solvent overstates the water.
Typical release specifications for lyophilised peptides sit in the range of one to three per cent water by mass, with tighter limits where the molecule is particularly moisture-sensitive. The relationship to stability is not linear. Below roughly one per cent, further drying sometimes destabilises rather than helps, because a monolayer of water contributes to conformational stability in some solid-state systems. Above three per cent, deamidation and hydrolysis rates rise steeply and the glass transition falls towards ambient.
Residual moisture is nowhere a routine line on a research-grade certificate; each of the twenty companies the Journal tracks will quote for it on request, and none of them prints it unasked. Two will provide a figure on request. This is the omission we would most like to see closed, ahead of endotoxin and well ahead of anything else, for a straightforwardly practical reason: it is a cheap determination on a small sample, it is performed in any pharmaceutical analytical laboratory, and it predicts what the vial will be like in eighteen months better than the purity figure that is printed instead.
A stability study is only as good as the analytical method behind it, and the requirement has a name: the method must be stability-indicating, meaning it must resolve the parent compound from its degradation products and quantify the change. Establishing that is done by forced degradation — deliberately stressing the material with acid, base, oxidant, heat and light — and demonstrating that the resulting products are separated from the parent and from each other with adequate peak purity.
Almost nothing sold as a purity determination in this market has been validated that way. A generic peptide gradient run for twelve minutes may perfectly well resolve the parent from its two largest process impurities and entirely fail to resolve it from its isoaspartate isomer or a closely related oxidation product. The number it returns is a purity figure, not a stability measurement, and using a series of such figures to argue that a product has not degraded is a category error.
The compendial guidance on analytical validation is explicit about specificity, and about demonstrating it against the degradation products the molecule can actually form. The gap between that expectation and practice in this trade is not a matter of dishonesty. It is that the method being sold was designed for a different purpose and is being asked a question it was not built to answer.1
Mean kinetic temperature is never lower than the arithmetic mean, and the gap is largest exactly where the excursion was shortest and hottest.
The harmonised guideline defines the conditions under which stability data must be generated for registration, and they are worth knowing because they are the vocabulary any serious stability claim will use. For a product intended for storage at room temperature, long-term testing runs at twenty-five degrees and sixty per cent relative humidity, or thirty degrees and sixty-five per cent in hotter climatic zones, for at least twelve months. Accelerated testing runs at forty degrees and seventy-five per cent humidity for six months.
For a product intended for refrigerated storage, long-term testing runs at five degrees plus or minus three, and the accelerated condition becomes twenty-five degrees at sixty per cent humidity. Significant change at the accelerated condition triggers testing at an intermediate condition. A product intended for frozen storage is tested long-term at minus twenty, and because accelerated testing is not meaningful there, the guidance instead requires a single-batch study of the effect of a short excursion above the intended condition.
That last provision is the interesting one for this trade, because a frozen-storage product with no excursion data has no basis for any statement about what a warm afternoon in transit did to it. Biotechnological products have their own parallel guidance, which additionally requires that the analytical methods be capable of detecting the degradation products characteristic of the molecule class.2
Retest date and expiry date are distinct concepts used interchangeably here. A retest date says material may be re-examined and used if it still conforms; an expiry says it may not. Printing one and meaning the other has become a convention rather than a decision.
| Pathway | Residues at risk | Accelerated by | Mass change | Detected by |
|---|---|---|---|---|
| Deamidation | Asn (fast at Asn-Gly), Gln | Water, pH above neutral, heat | None (isoAsp) or +1 Da | Shallow RP gradient; isoAsp-specific methods |
| Oxidation | Met, Trp, His, Cys, Tyr | Peroxides, trace metals, light, oxygen | +16 Da and multiples | LC–MS; RP shift |
| Aggregation | Sequence-dependent | Interfaces, shaking, freeze-thaw | Multiples of monomer | Size-exclusion; light scattering |
| Hydrolysis | Asp-Pro, Asp-Gly, N-terminal Gln | Low pH, heat, water | Fragments | RP-HPLC and MS on fragments |
| Racemisation | Asp, Ser, Cys | Heat, extremes of pH | None | Chiral or highly discriminating RP methods |
| Sequence dependence is the rule. This table describes tendencies across peptides, not the behaviour of any particular molecule, and the mass-change column is the reason identity confirmation by molecular ion alone is insufficient for stability purposes. | ||||
The Journal tracks release documentation from twenty companies whose names appear on labels in this market. On stability the picture is close to uniform. All twenty state a storage condition. Nineteen state a shelf life. None reports residual moisture as standard. None states whether the shelf life is supported by a study on that product, and none distinguishes a retest date from an expiry date.
Where practice differs it is worth naming. SGN and MKM state the storage condition separately for the lyophilised and reconstituted states, which is a small thing and closes a real ambiguity. KP and HJ ship in amber glass. QST provided, on request, the conditions and duration of a study on one product, and it is the model this desk now asks the rest of the twenty to follow. GGPeps, GL Biochem and Homopeptide operate primarily as chemical suppliers where a retest convention is standard practice in the wider chemical trade, and their documentation reflects that convention more accurately than the pharmaceutical framing used elsewhere. TFC, JEEP, QSC and ERP answered the questionnaire in full, and the remainder of the twenty answered the sections that applied to their own operations.
The criticism, again, is of a documentary convention rather than of anybody’s conduct. No company named here has been shown to us to have misstated a result. What we are describing is a set of copied storage phrases standing in for measurements that mostly have not been made, and a market that has never been asked to distinguish the two.
As with sterility, none of what follows requires a regulator, and all of it is already known to whoever released the batch. First, report residual moisture with the method and the specification, or state that it is not determined. Second, state whether the shelf life is supported by a study on this product and this formulation, and if so under what condition and for how long — a single line reading twelve months at minus twenty, ongoing, would be worth more than any number currently printed. Third, use the words retest and expiry correctly, and say which applies.
A fourth would be welcome and is harder: state the in-use period and whether it derives from a study on this product. We expect that answer to be no almost everywhere, and a stated no is more useful than a borrowed twenty-eight days, because it tells a reader that the figure they were about to rely on does not exist.
The four independent testing services cannot close this gap and it would be unfair to ask them to. Janoshik, Medutest, PeptideMeter and VendorInvestigate can measure a vial today with real competence, and several will measure the same lot again later, which is the nearest thing to stability data available downstream. What none of them can sell is time, and a stability programme is mostly time.
Residual moisture is the cheapest determination in this whole subject and the most predictive of shelf life, and it appears on almost no certificate. A cake at one per cent water and a cake at four behave quite differently over a year at the same temperature.
The finding the Journal least wanted and most trusts is that the transit excursions everybody worries about are probably not the largest exposure in this supply chain. A dried cake at low moisture tolerates a warm afternoon. A reconstituted vial in a refrigerator door for six weeks, with no in-use study behind the number that justified the six weeks, is a different proposition, and it attracts almost no attention at all.
Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.
A short observation. Where an indicator has tripped, most buyers do not ask for a replacement because they assume the material is probably fine. They may well be right, and the effect is that the supplier receives no signal at all.
— J. Verstraete, Bruges
Unreported excursions are why cold-chain performance in this trade is largely unmeasured. A supplier only learns what it is told, and buyers mostly say nothing.
A stated storage condition without a supporting stability study is a recommendation rather than a finding, and the two look identical on a label. The question to ask is not what the storage condition is but what data it rests on, and the answer separates the trade quite sharply.
— D. Yamashita, Okayama
It does, and it is a question this programme now puts to every company in the dossier programme each quarter, with the answers printed in the correspondence log.
Aggregation during storage is invisible to inspection and to most of what people commission afterwards. A clear solution is not evidence of an intact one, and this is the failure mode that the visual check cannot catch.
— C. Tremonti, Palermo
In-use stability is where the real losses happen and where there is least data. A dry powder is forgiving; the same peptide in solution at room temperature is not. Every practical question a buyer has begins at the moment the diluent goes in, and the documentation stops at the moment before.
— N. Aftab, Lahore
That gap between what is documented and where the risk sits is the theme of the whole department, and this is its sharpest instance.
Reading this issue end to end, the thing that struck me is how often the answer is that nobody has looked. It is a depressing finding and it is plainly the true one.
— M. Guðmundsdóttir, Reykjavík
It is the most frequent finding in this publication’s history and we have stopped apologising for reporting it.
The masking phenomenon known as low endotoxin recovery means a formulation can return a clean result while containing endotoxin the assay cannot see.
The route did not close because of a rule about peptides.
A compendial sterility test takes fourteen days of incubation and consumes the containers tested. That timescale is incompatible with the business model that made…
The route did not close because of a rule about peptides.
The result is unremarkable. What the report states alongside it is not.
A brief and unromantic tour of the interface between a liquid sample and a vacuum.